logo
The one change that worked: I stood up to my inner critic and I've never looked back

The one change that worked: I stood up to my inner critic and I've never looked back

The Guardian16-06-2025
I wish I could say that if my teenage self had a window to the future, she would be proud of the person I've become. But, in truth, I think she would dislike me just as much as she disliked herself. Back then, I could have spoken for hours about all of the reasons I hated the person I was. And that wasn't something I believed would change. I used to be all-consumed by my inner critic: the critical voice in my head was much louder than any rational thoughts or words of affirmation others offered me.
I had an eating disorder. Each day was a monotonous cycle of exercising as much as possible and eating as little as I could get away with. I was miserable, and it was all because of the cage I'd built within my own mind. This is not something unique to people with eating disorders. I've realised, after sharing my story online, that so many people have this unkind voice in their heads, critiquing their every move. And that when you start to talk back, your life improves in ways you wouldn't expect.
Before I knew I was controlled by my inner critic, I took everything it said as fact. My self-esteem was so low. I'd stand in front of the mirror and the barrage of insults would begin: ugly, fat, useless, unlovable, spotty, disgusting. If someone had said these words to me every day, I'm sure I would have recognised it as bullying. But coming from my own mind, they felt justified and accurate.
But one day, standing in front of my bedroom mirror, I realised this was just a voice. This voice that took such pleasure in reminding me how utterly worthless I was, wasn't actually my own. It was a separate entity to me. Suddenly, everything changed. Every time I noticed my inner critic calling me lazy and unproductive, I started to stick up for myself. I would tell myself: 'Actually, I don't need to be doing anything now, I deserve to rest'. If it called me ugly, I would remind myself that I didn't need to be so hard on myself.
For the last five years, I tried hard to say nice things about myself in my head until neutral self-talk felt normal. It hurts to know how unkind to myself I was. I feel incredibly sad for that version of me.
While I occasionally still have to remind myself not to be self-critical, my inner critic has slipped away. Therapy and journalling has helped me to find joy in self-acceptance. I can make a mistake and instead of berating myself, I can reassure myself. I no longer shrink myself to please my inner critic, I have learned to stand up for myself. I know now that just because you think something that doesn't make it true.
How to Talk to Yourself by Ro Mitchell is published by Bluebird. To support the Guardian order your copy at guardianbookshop.com. Delivery charges may apply.
In the US, help is available at nationaleatingdisorders.org or by calling ANAD's eating disorders hotline at 800-375-7767. In the UK, Beat can be contacted on 0808-801-0677. In Australia, the Butterfly Foundation is at 1800 33 4673. Other international helplines can be found at Eating Disorder Hope
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Edwards Lifesciences raises annual sales forecast on strong demand for heart devices
Edwards Lifesciences raises annual sales forecast on strong demand for heart devices

Reuters

time4 hours ago

  • Reuters

Edwards Lifesciences raises annual sales forecast on strong demand for heart devices

July 24 (Reuters) - Edwards Lifesciences (EW.N), opens new tab raised its 2025 sales forecast on Thursday, citing strong demand for its artificial heart valves and other medical devices, after posting better-than-expected results for the second quarter. Shares of the California-based company rose about 8% in extended trading. Investor confidence in medical device makers has climbed in recent quarters, underpinned by robust demand for surgical procedures, particularly among older adults. Edwards now expects full-year sales in the range of $5.9 billion to $6.1 billion, having raised the lower end of its previous forecast from $5.7 billion while maintaining the upper end. Earlier on Thursday, larger rival Boston Scientific (BSX.N), opens new tab also raised its annual profit forecast, buoyed by strong demand for its heart devices. Sales of Edwards' flagship transcatheter aortic valve replacement (TAVR) devices, used in minimally invasive heart surgeries, jumped 8.9% to $1.13 billion in the quarter ended June 30, topping analysts' average estimate of $1.09 billion, according to data compiled by LSEG. On an adjusted basis, Edwards earned 67 cents per share in the second quarter, beating Wall Street's estimate of 62 cents per share. It reported revenue of $1.53 billion, surpassing market expectation of $1.49 billion. The company said it now expects its 2025 adjusted earnings to come in at the high end of its earlier forecast range of $2.40 to $2.50 per share. Edwards said its forecast factors in current tariffs and warned that any changes or new tariffs could significantly impact future results.

Hospital worker arrested over assault of patient in Northampton
Hospital worker arrested over assault of patient in Northampton

BBC News

time9 hours ago

  • BBC News

Hospital worker arrested over assault of patient in Northampton

A member of staff at a psychiatric hospital has been arrested in connection with an alleged assault on a Police said a woman, from Northampton, was arrested on suspicion of assault and ill-treatment or wilful neglect following an incident on 29 June and has been released on bail. St Andrew's Healthcare in Northampton, which is used by the NHS, said it had suspended a number of staff and launched an investigation into the hospital said it was "taking urgent steps to reinforce high-quality care across all wards" after NHS England restricted new referrals to the hospital. A Northamptonshire Police spokesman said: "Detectives are investigating a report of an assault which is alleged to have taken place at St Andrew's Hospital, Northampton, on 29 June.""Due to the vulnerability of the victim in this case, officers conducting inquiries as part of this investigation have been in contact with the CQC and local safeguarding leads," they added. St Andrew's Healthcare is a charity that cares for people with complex mental health hospital cares for about 600 patients and employs more than 4,000 people across four locations. Restricted referrals The CQC said it had carried out an inspection of inpatient services at the hospital on 11 July. A spokesman for the regulator said: "As a result, CQC took action requiring [St Andrew's Healthcare] to make immediate, specific improvements around safety. "They are being monitored closely to make sure this happens, and a report containing the full findings from the inspection will be published on CQC's website when the usual quality assurance processes have been completed," they added. NHS England said St Andrew's Healthcare looked after patients with "very complex mental health needs from all over the UK". "The safety of patients is our first priority and commissioners working together with the CQC have restricted referrals to St Andrew's Northampton site," it England said it had "taken immediate action together with St Andrew's to ensure the charity keeps patients safe, meets contractual obligations, and prioritises a targeted programme of support which operates in line with CQC requirements". Follow Northamptonshire news on BBC Sounds, Facebook, Instagram and X.

GSK's blood cancer drug gets EU approval
GSK's blood cancer drug gets EU approval

Reuters

time9 hours ago

  • Reuters

GSK's blood cancer drug gets EU approval

July 24 (Reuters) - The European Union has approved GSK's (GSK.L), opens new tab drug Blenrep to treat relapsed or treatment-resistant forms of a cancer affecting blood plasma cells, the British drugmaker said on Thursday. EU regulators approved Blenrep after phase III trials showed the drug, when used in combination with standard treatments, extended progression-free survival and improved overall survival in patients with relapsed or refractory multiple myeloma, GSK said. The approval comes a day after the U.S. Food and Drug Administration extended its review of the drug as a combination treatment for the same illness. The FDA's panel of independent experts had last week recommended against the drug, citing concerns about previously documented risks of eye-related side effects. The EU approval marks the sixth regulatory nod for Blenrep combinations, with applications still under review across all major markets. The drug delivers a cell-killing agent directly to tumour cells while limiting damage to healthy tissue — unlike conventional chemotherapy. Multiple myeloma is the third most common blood cancer globally and is generally considered treatable but not curable. It affects the immunity-boosting plasma white blood cells.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store